Citius Oncology (CTOR) Competitors $1.70 -0.09 (-5.03%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.75 +0.05 (+2.71%) As of 10/17/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTOR vs. ESPR, SIGA, MNPR, CMPS, SVRA, AQST, MLTX, ARCT, ZVRA, and NAGEShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Esperion Therapeutics (ESPR), Siga Technologies (SIGA), Monopar Therapeutics (MNPR), COMPASS Pathways (CMPS), Savara (SVRA), Aquestive Therapeutics (AQST), MoonLake Immunotherapeutics (MLTX), Arcturus Therapeutics (ARCT), Zevra Therapeutics (ZVRA), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Esperion Therapeutics Siga Technologies Monopar Therapeutics COMPASS Pathways Savara Aquestive Therapeutics MoonLake Immunotherapeutics Arcturus Therapeutics Zevra Therapeutics Niagen Bioscience Citius Oncology (NASDAQ:CTOR) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Is CTOR or ESPR more profitable? Citius Oncology has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -35.84%. Esperion Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -51.93% -22.17% Esperion Therapeutics -35.84%N/A -28.41% Does the media refer more to CTOR or ESPR? In the previous week, Esperion Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Citius Oncology. Esperion Therapeutics' average media sentiment score of 0.40 beat Citius Oncology's score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in CTOR or ESPR? 70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 6.7% of Citius Oncology shares are held by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, CTOR or ESPR? Citius Oncology has higher earnings, but lower revenue than Esperion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/AEsperion Therapeutics$332.31M1.67-$51.74M-$0.49-5.61 Do analysts recommend CTOR or ESPR? Citius Oncology presently has a consensus price target of $6.00, suggesting a potential upside of 252.94%. Esperion Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 154.55%. Given Citius Oncology's higher possible upside, equities analysts plainly believe Citius Oncology is more favorable than Esperion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, CTOR or ESPR? Citius Oncology has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. SummaryCitius Oncology and Esperion Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.49M$3.40B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.80%P/E RatioN/A23.1685.4627.13Price / SalesN/A268.39519.28179.84Price / CashN/A47.1837.2361.22Price / Book2.6610.4112.236.52Net IncomeN/A-$52.77M$3.33B$276.93M7 Day Performance-0.58%2.31%1.17%1.94%1 Month Performance-2.86%11.13%6.14%2.19%1 Year Performance37.10%11.12%59.99%35.00% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology2.0595 of 5 stars$1.70-5.0%$6.00+252.9%+57.4%$149.49MN/A0.00N/ANews CoverageESPREsperion Therapeutics3.7558 of 5 stars$3.08-1.4%$7.00+127.6%+30.3%$619.98M$332.31M-6.28200SIGASiga Technologies2.1424 of 5 stars$8.45+2.7%N/A+17.4%$606.54M$138.72M7.5040Options VolumeMNPRMonopar Therapeutics3.3102 of 5 stars$98.29-1.2%$97.33-1.0%+1,303.3%$605.65MN/A-29.4810CMPSCOMPASS Pathways2.9707 of 5 stars$6.29-0.1%$16.29+159.1%+4.0%$600.11MN/A-3.40120News CoverageGap DownSVRASavara3.0775 of 5 stars$3.45-0.4%$7.50+117.7%-1.1%$595.42MN/A-6.8920Trending NewsAnalyst UpgradeAnalyst RevisionAQSTAquestive Therapeutics2.2882 of 5 stars$5.89-1.4%$10.29+74.8%+43.9%$584.88M$44.13M-8.38160News CoverageInsider TradeMLTXMoonLake Immunotherapeutics2.886 of 5 stars$9.11+5.2%$36.00+295.3%-81.0%$581.41MN/A-3.262Trending NewsGap DownHigh Trading VolumeARCTArcturus Therapeutics3.5701 of 5 stars$20.87-0.7%$50.57+142.3%+0.3%$568.05M$152.31M-9.38180Gap DownZVRAZevra Therapeutics2.6236 of 5 stars$10.11-5.1%$24.00+137.4%+26.7%$567.47M$23.61M-48.1420Analyst ForecastHigh Trading VolumeNAGENiagen Bioscience2.6254 of 5 stars$7.09-2.3%$13.42+89.3%N/A$565.45M$116.30M33.76120 Related Companies and Tools Related Companies Esperion Therapeutics Competitors Siga Technologies Competitors Monopar Therapeutics Competitors COMPASS Pathways Competitors Savara Competitors Aquestive Therapeutics Competitors MoonLake Immunotherapeutics Competitors Arcturus Therapeutics Competitors Zevra Therapeutics Competitors Niagen Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
